News Releases

News Releases

June 2022

Jun 5th 2022

Data from the PARADIGM Trial in Chemotherapy-naive Japanese Patients with Unresectable Advanced Recurrent Colorectal Cancer and Wild-type RAS Gene Presented at the ASCO 2022 Plenary Session

May 2022

May 31st 2022

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

May 26th 2022

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

May 26th 2022

Approval of Partial Change to the Manufacturing and Marketing Approval for ADCETRIS® as a First-line Treatment of CD30-Positive Hodgkin Lymphoma in Pediatric Patients

March 2022

Mar 25th 2022

Takeda’s ALUNBRIG® (brigatinib) approved by China’s NMPA as a new treatment option for patients with ALK-positive non-small cell lung cancer

January 2022

Jan 10th 2022

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

December 2021

Dec 7th 2021

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting

October 2021

Oct 27th 2021

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

September 2021

Sep 15th 2021

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

Sep 1st 2021

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

1

2

3

4

5

...

Explore More

Oncology Pipeline

Oncology Pipeline

Discovering and developing innovative therapies to deliver potentially transformative treatments

R&D Approach

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline

Leadership Team

Leadership Team

Our Executive Leadership team is designed to drive customer proximity, nimbleness, agility and accountability